AstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
Almost £10 billion has been wiped from Anglo-Swedish pharma giant AstraZeneca’s stock market valuation after much-anticipated immuno-oncology trial results failed to show benefit over standard lung cancer therapy.